AU2014318615B2 - Methods and compositions comprising purified recombinant polypeptides - Google Patents

Methods and compositions comprising purified recombinant polypeptides Download PDF

Info

Publication number
AU2014318615B2
AU2014318615B2 AU2014318615A AU2014318615A AU2014318615B2 AU 2014318615 B2 AU2014318615 B2 AU 2014318615B2 AU 2014318615 A AU2014318615 A AU 2014318615A AU 2014318615 A AU2014318615 A AU 2014318615A AU 2014318615 B2 AU2014318615 B2 AU 2014318615B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2014318615A
Other languages
English (en)
Other versions
AU2014318615A1 (en
AU2014318615A9 (en
Inventor
Annamarie AMURAO
Saloumeh Kadkhodayan Fischer
Susan C. FISHER
Jayme Franklin
John Lowe
Atia NAIM
Ailen M. SANCHEZ
Christopher A. TESKE
Martin Vanderlaan
Corazon Victa
X. Christopher YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2014318615A1 publication Critical patent/AU2014318615A1/en
Publication of AU2014318615A9 publication Critical patent/AU2014318615A9/en
Priority to AU2020200502A priority Critical patent/AU2020200502B9/en
Application granted granted Critical
Publication of AU2014318615B2 publication Critical patent/AU2014318615B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014318615A 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides Active 2039-05-29 AU2014318615B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200502A AU2020200502B9 (en) 2013-09-13 2020-01-23 Methods and compositions comprising purified recombinant polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13
US61/877,517 2013-09-13
PCT/US2014/055387 WO2015038888A1 (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200502A Division AU2020200502B9 (en) 2013-09-13 2020-01-23 Methods and compositions comprising purified recombinant polypeptides

Publications (3)

Publication Number Publication Date
AU2014318615A1 AU2014318615A1 (en) 2016-04-21
AU2014318615A9 AU2014318615A9 (en) 2016-06-16
AU2014318615B2 true AU2014318615B2 (en) 2020-03-12

Family

ID=52666315

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014318615A Active 2039-05-29 AU2014318615B2 (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides
AU2020200502A Active AU2020200502B9 (en) 2013-09-13 2020-01-23 Methods and compositions comprising purified recombinant polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200502A Active AU2020200502B9 (en) 2013-09-13 2020-01-23 Methods and compositions comprising purified recombinant polypeptides

Country Status (18)

Country Link
US (8) US9920120B2 (https=)
EP (3) EP4331605A3 (https=)
JP (4) JP6751344B2 (https=)
KR (2) KR102571391B1 (https=)
CN (2) CN120904322A (https=)
AR (3) AR097651A1 (https=)
AU (2) AU2014318615B2 (https=)
BR (1) BR112016004413A2 (https=)
CA (2) CA3184564A1 (https=)
HK (1) HK1225988A1 (https=)
IL (2) IL244149B2 (https=)
MX (3) MX382393B (https=)
MY (2) MY193481A (https=)
NZ (3) NZ756749A (https=)
RU (1) RU2671481C2 (https=)
SG (2) SG11201601823TA (https=)
WO (1) WO2015038888A1 (https=)
ZA (4) ZA201601965B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970378T3 (da) 2013-03-15 2021-08-23 Biogen Ma Inc Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
JP6599773B2 (ja) 2013-03-15 2019-10-30 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド 抗体を精製するための方法
EP4331605A3 (en) * 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
JP7073253B2 (ja) * 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
IL257146B2 (en) * 2015-08-21 2025-01-01 Hoffmann La Roche Method for reducing host cell proteins by affinity chromatography
CA3020808A1 (en) * 2016-04-14 2017-10-19 Lonza Ltd Compositions and methods for the detection of host cell proteins
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10688412B2 (en) * 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
EP3510042B1 (en) 2016-09-07 2024-05-22 GlaxoSmithKline Intellectual Property Development Limited Methods for purifying antibodies
JP7471819B2 (ja) * 2016-10-06 2024-04-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 工程不純物への結合が低下している抗体
EA201990986A1 (ru) 2016-10-25 2019-09-30 Ридженерон Фармасьютикалз, Инк. Способы и системы анализа хроматографических данных
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3826743A4 (en) * 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
CA3127174A1 (en) 2019-01-23 2020-07-30 Daiichi Sankyo Company, Limited Methods for purifying antibodies comprising of a process by using activated carbon materials
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
MX2021012677A (es) * 2019-04-17 2021-11-12 Regeneron Pharma Identificacion de proteinas de celulas huesped.
KR102799360B1 (ko) * 2019-05-21 2025-04-25 리제너론 파아마슈티컬스, 인크. 숙주 세포 단백질 동정 및 정량화 방법
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
EP4038083A1 (en) * 2019-10-04 2022-08-10 Merck Patent GmbH Purification of proteins and viral inactivation
EP4096802A4 (en) * 2020-01-29 2024-07-03 Merck Sharp & Dohme LLC METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
JP2022023813A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
EP4334333A4 (en) * 2021-05-03 2025-07-02 Agilent Technologies Inc CHIMERIC IMMUNOGENS AND METHODS FOR MAKING POLYCLONAL ANTIBODIES AGAINST SPECIFIC EPITOPES
EP4518839A2 (en) * 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
IL317083A (en) 2022-06-17 2025-01-01 Apogee Biologics Inc Antibodies that bind interleukin 13 and methods of use
EP4637820A1 (en) * 2022-12-19 2025-10-29 Eli Lilly and Company Methods of reducing contaminants in protein purification
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050071A2 (en) * 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2085983T3 (es) 1989-12-20 1996-06-16 Schering Corp Antagonistas de anticuerpos de la interleuquina-4 humana.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5550045A (en) 1992-05-15 1996-08-27 Unilever Patent Holdings, B.V. Cloning and expression of DNA encoding a ripening form of a polypeptide having rhamnogalcturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ATE474925T1 (de) 1993-05-17 2010-08-15 Genentech Inc Rekombinante cho zell sialidase
DK0721469T3 (da) 1993-09-02 2000-05-01 Dartmouth College Anti-gp39-antistoffer og anvendelse deraf
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
WO1997015663A1 (en) 1995-10-23 1997-05-01 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
KR20000070034A (ko) 1997-01-10 2000-11-25 아스트루 마이클 제이 항 ｃｄ40ｌ 화합물로 신염성 루푸스를 치료하는 방법
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
WO2000044407A2 (en) 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
CA2404763A1 (en) 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
WO2002055100A2 (en) 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
CA2452058A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
PT1449850E (pt) 2001-08-31 2011-02-02 Kyowa Hakko Kirin Co Ltd Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20040023337A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003040164A2 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
HK1079882B (en) 2002-06-14 2011-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing colitis involving il-13 and nk-t cells
JP2006503018A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
CA2555306A1 (en) 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
ES2339953T5 (es) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
AU2005318919B2 (en) 2004-12-24 2010-09-09 Commonwealth Scientific And Industrial Research Organisation Pesticide compositions and methods
AU2006223180B2 (en) 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
CN101218247A (zh) 2005-04-11 2008-07-09 米德列斯公司 利用hcic和离子交换层析的蛋白质纯化
TWI372763B (en) 2005-06-17 2012-09-21 Wyeth Llc Methods of purifying anti a beta antibodies
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
AU2006296399B2 (en) * 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
UA99097C2 (ru) 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
MX2008013394A (es) 2006-04-21 2008-10-31 Wyeth Corp Metodos para tamizado de alta emision de lineas celulares.
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
AR062947A1 (es) 2006-09-21 2008-12-17 Verenium Corp Fosfolipasas acidos nucleicos que las codifican y metodos para prepararlas y usarlas
KR20150002879A (ko) 2006-10-02 2015-01-07 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
DK2069798T3 (da) 2006-10-04 2014-06-16 Genentech Inc Elisa til vegf
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2527366B1 (en) 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
CA2701788C (en) 2007-10-05 2017-06-13 Genentech, Inc. Humanized beta-amyloid antibody for treating ocular diseases
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
EP2631302A3 (en) 2008-03-31 2014-01-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
MX2011004199A (es) 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
BRPI0919547A2 (pt) 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-12 e métodos de purificação do mesmo
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
MX369106B (es) 2010-05-17 2019-10-29 Chiome Bioscience Inc Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo.
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
WO2012006341A2 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
WO2012047732A2 (en) 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
AR084020A1 (es) * 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
TWI732259B (zh) 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
RU2665810C2 (ru) * 2011-10-31 2018-09-04 Дженентек, Инк. Содержащие антитела составы
EP2782932A1 (en) * 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
ES2690213T3 (es) 2011-12-15 2018-11-19 Prestige Biopharma Pte. Ltd. Un método de purificación de anticuerpos
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2915378T3 (es) * 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) * 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050071A2 (en) * 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Liu, H.F. et al, "Recovery and purification process development for monoclonal antibody production", mAbs (2010), vol. 2, no. 5, pages 480-499 *
VANDERLAAN, M. ET AL, "Hamster Phospholipase B-Like 2 (PLBL2): A Host-Cell Protein Impurity in Therapeutic Monoclonal Antibodies Derived from Chinese Hamster Ovary Cells", BIOPROCESS INTERNATIONAL, (2015), vol. 13, no. 4, pages 18 - 55 *

Also Published As

Publication number Publication date
WO2015038888A1 (en) 2015-03-19
KR20160052724A (ko) 2016-05-12
US20180273615A1 (en) 2018-09-27
US10597447B2 (en) 2020-03-24
ZA202101142B (en) 2022-09-28
ZA202201361B (en) 2023-11-29
JP6982027B2 (ja) 2021-12-17
MX2021005358A (es) 2021-06-30
US20180291095A1 (en) 2018-10-11
NZ718144A (en) 2022-05-27
IL320195A (en) 2025-06-01
JP6751344B2 (ja) 2020-09-02
AU2014318615A1 (en) 2016-04-21
CA2921999C (en) 2023-03-21
AU2014318615A9 (en) 2016-06-16
HK1225988A1 (zh) 2017-09-22
CN120904322A (zh) 2025-11-07
MY176026A (en) 2020-07-22
US10494429B2 (en) 2019-12-03
US10822404B2 (en) 2020-11-03
JP2022036971A (ja) 2022-03-08
NZ756749A (en) 2022-05-27
CA2921999A1 (en) 2015-03-19
EP4331605A2 (en) 2024-03-06
US10597446B2 (en) 2020-03-24
SG11201601823TA (en) 2016-04-28
IL244149B1 (en) 2025-05-01
ZA201601965B (en) 2018-11-28
US20160319012A1 (en) 2016-11-03
RU2016108828A (ru) 2017-10-18
US20250250333A1 (en) 2025-08-07
US20180291094A1 (en) 2018-10-11
AR133787A2 (es) 2025-11-05
AU2020200502B2 (en) 2022-03-10
EP4331605A3 (en) 2024-05-22
KR102571391B1 (ko) 2023-08-29
WO2015038888A9 (en) 2016-03-17
JP2024059617A (ja) 2024-05-01
US12312399B2 (en) 2025-05-27
US11667706B2 (en) 2023-06-06
JP2016539176A (ja) 2016-12-15
EP3683232A1 (en) 2020-07-22
MX2016003202A (es) 2016-06-07
RU2016108828A3 (https=) 2018-05-29
JP7489953B2 (ja) 2024-05-24
MY193481A (en) 2022-10-17
CA3184564A1 (en) 2015-03-19
RU2671481C2 (ru) 2018-10-31
ZA201801849B (en) 2021-07-28
KR20220034930A (ko) 2022-03-18
US20180312585A1 (en) 2018-11-01
BR112016004413A2 (pt) 2017-10-17
AU2020200502B9 (en) 2022-03-24
MX2021005364A (es) 2021-06-30
AR097651A1 (es) 2016-04-06
JP2019178139A (ja) 2019-10-17
NZ756750A (en) 2022-05-27
SG10201802525QA (en) 2018-04-27
US9920120B2 (en) 2018-03-20
US20210115126A1 (en) 2021-04-22
AR118560A2 (es) 2021-10-20
IL244149A0 (en) 2016-04-21
AU2020200502A1 (en) 2020-02-13
EP3043820A1 (en) 2016-07-20
CN105722532A (zh) 2016-06-29
MX382393B (es) 2025-03-13
EP3043820A4 (en) 2017-07-12
KR102373930B1 (ko) 2022-03-11
US20230250165A1 (en) 2023-08-10
IL244149B2 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
US12312399B2 (en) Methods and compositions comprising purified recombinant polypeptides
US20180327446A1 (en) Purification of fkpa and uses thereof for producing recombinant polypeptides
HK40106712A (en) Methods and compositions comprising purified recombinant polypeptides
RU2793783C1 (ru) Способы и композиции, включающие очищенные рекомбинантные полипептиды

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: EBGLYSS EBRIKIZUMA

Filing date: 20240529

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: EBGLYSS LEBRIKIZUMAB

Filing date: 20240529

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: EBGLYSS LEBRIKIZUMAB

Filing date: 20240529

Extension date: 20390529